138 results about "Fat diet" patented technology

The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (HPMC) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and / or prebiotics, and / or narrow spectrum antibiotics / anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota.

The subject disclosure provides compositions for reducing serum cholesterol and / or triglyceride levels in subjects. These compositions can comprise racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject. Alternatively, compositions comprising racemic β-hydroxybutyrate or D-β-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic β-hydroxybutyrate or D-β-hydroxybutyrate, esters of D-β-hydroxybutyrate, oligomers of D-β-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol, R-1,3 butandiol or combinations thereof can be formulated as nutritional supplements (also referred to as nutritional compositions) or incorporated into therapeutic compositions containing a) anti-hypertensive agents; b) anti-inflammatory agents; c) glucose lowering agents; or d) anti-lipemic agents) which are administered to a subject, optionally in combination with a low fat diet, in order to cause a reduction or lowering of: serum cholesterol levels; triglyceride levels; serum glucose levels, serum homocysteine levels, inflammatory proteins (e.g., C reactive protein) and / or hypertension in treated subjects. Alternatively, compositions disclosed herein can be administered alone, or in combination with other therapeutic agents to prevent or reverse vascular disease.

The embodiment of the invention provides a dried vegetarian meat slice and a processing method thereof. The dried vegetarian meat slice comprises the following raw materials of, in parts by weight, 20-40 parts of vegetarian meat blank, 8-15 parts of soybean isolate protein powder, 8-15 parts of wheat protein powder, 1-5 parts of starch, 0.1-3 part of sodium alginate, 0.5-1.5 parts of monascus red,10-18 parts of vegetable oil, 5-15 parts of seasonings and 20-45 parts of water, the vegetarian meat blank is prepared by uniformly mixing 30-50 parts of soybean protein, 20-40 parts of wheat protein, 5-10 parts of potato starch, 3-5 parts of white granulated sugar, 1-2 parts of salt, 1-2 parts of light soy sauce, 3-5 parts of spice powder and 10-20 parts of water, and carrying out twin-screw extrusion treatment at 80-160 DEG C. According to the embodiment of the dried vegetarian meat slice and the processing method thereof, the dried vegetarian meat slice which has elasticity and chewiness similar to those of meat, is nutritional and delicious is obtained, and the dried vegetarian meat slice conforms to the current high-protein low-fat diet pursuit of people, and has favorable market prospects.

The invention discloses an application of lactobacillus rhamnosus CCFM1060 in preparation of functional microbial agents, foods and / or medicines. The lactobacillus rhamnosus CCFM1060 can tolerate thegastrointestinal environment of the human body, significantly improve fasting blood glucose rise and abnormal oral glucose tolerance of type 2 diabetics caused by high fat diet and STZ injection, reduce the area under the curve during glucose tolerance drug administration, and relieve insulin resistance; remarkably improve the increase of total cholesterol content and the increase of low-density lipoprotein cholesterol in serum of type 2 diabetics caused by high-fat diet and STZ injection; obviously relieve the inflammatory state of the liver; and significantly reduce pancreatic and liver pathological injuries caused by high-fat diet and STZ injection. The lactobacillus rhamnosus CCFM1060 has relatively strong adsorption capacity on perfluorooctanoic acid (PFOA), and has the capacity of relieving the toxicity of the PFOA.

The invention provides an application of lactobacillus plantarum powder in regulating fat metabolism and intestinal flora of fat rats. The lactobacillus plantarum powder can reduce the in-vivo fat content, increased under induction of high-fat diet, of rats and reduce the body fat rate; the FFA content, increased under induction of high-fat diet, in serum of rats can be remarkably reduced; meanwhile, the TG content in the serum of obese rats can be reduced, and the HDL-C content is increased; the lipid metabolism function of the livers of the obese rats can be improved, and activation of a fatty acid synthesis pathway of the obese rats is inhibited; the condition of intestinal flora disorder of the obese rats can be improved, and the flora richness, flora diversity, flora structure and composition of the obese rats can be maintained; increase of relative abundance of firmicutes is inhibited; the relative abundance of bacteroides is improved; the relative abundance ratio of the firmicutes to the bacteroides in intestinal tracts of rats under the condition of high fat diet is reduced; and the similarity of intestinal flora of the obese rats and healthy rats is increased.

The invention discloses lactobacillus plantarum with functions of losing weight and reducing lipid and an application thereof, and belongs to the technical field of microorganisms; the lactobacillus plantarum LP-KFY04 is lactic acid bacteria (LAB), and the preservation number is CGMCC No. 15651; lactobacillus plantarum KFY04 is separated from yoghourt and is used for mice maintaining 45% fat diet;then liver and serum samples are obtained, and gene expression related to the TG level, oxidation, inflammation and PPAR pathway is detected to evaluate the influence of LP-KFY04 on obesity, oxidation and inflammation; and results show that the LP-KFY04 can be used for relieving obesity of mice induced by high fat diet, and the LP-KFY04 can effectively reduce liver injury and fat accumulation caused by obesity.

The invention provides a lactobacillus plantarum BUFX (Lactobacillus plantarum) and application thereof in metabolic syndrome, which relate to the technical field of microorganisms and application of the microorganisms. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC), and the preservation number is CGMCC No.22172. The lactobacillus plantarum is separated and screened from feces of adults, can promote glucose consumption of HepG2 hepatoma carcinoma cells, inhibits alpha-amylase activity, can remarkably reduce the weight and blood fat content of high-fat diet mice, improves glucose tolerance, and has important application significance for preventing or treating metabolic diseases such as diabetes, obesity and the like.

The invention relates to a preparation method for papaya extract and the novel use of the papaya extract for the treatment of hepatic fibrosis. The preparation method comprises the steps of papaya extraction, extraction separation, resin adsorption and the like. According to the preparation method and the use, a high-fat diet molding technology is used for making researches on the use and effects of the papaya extract in an animal body, and experimental results show that the papaya extract has high liver protection and lipid lowering activity and good curative effects on hepatic fibrosis and can remarkably inhibit hepatic fibrosis.

The invention discloses application of ampelopsin in preparing medicines for treating obesity, and relates to preparation and application of flavonoids compounds. The ampelopsin is used for preparing medicines or health products for treating the obesity, including oral tablets, capsules, granules, oral solution, sustained-release agents, pills and injection solution for treating the obesity, and pharmaceutically acceptable conventional formulations. The ampelopsin has obvious weight-losing effect on obese mice and overweight mice induced by high-fat diet; after the ampelopsin is poured into stomachs of the obese mice in a dose of 25.0mg / kg for 2 weeks, the abdominal fat is obviously reduced, shoulder fat cells are obviously shrunk, the weight is reduced to be normal, and the mice are generally good in conditions, freely acts and have smooth hairs. The maximum tolerance does of the mice through stomach perfusion can reach 18g / kg.

The present invention discloses a Gynostemma pentaphylla functional yoghurt product and a preparation method thereof. Lactobacillus plantarum HLX37 is added into fresh milk, 3wt.% Gynostemma pentaphyllum leach liquor, sucrose and pure water, and the yoghurt product is prepared by high-temperature fermentation process. The prepared yoghurt product can significantly reduce the damage of rat liver cells caused by high-fat diet, significantly reduce serum cholesterol and glucose levels in hyperlipidemia rats, and has a pharmacological effect in resisting lipid peroxidation in both inactivated and non-inactivated state; meanwhile, the yoghurt product can also significantly improve the immunity of rat intestine. The yoghurt product can be applied to mitigate or reduce the occurrence of high blood lipid, high blood pressure, high blood sugar symptoms for human beings, and can improve the immune function of human body at the same time, playing a good health-care role for human health.

The invention relates to table adjustment wine for reducing blood pressure and blood fat. The wine is health-care and comprises the following raw materials: raw hawthorn, curcuma longa, giant knotweed rhizome, apocynum venetum, fiveleaf gynostemma herb, white paeony root, astragalus root, radix polygoni multiflori preparata, cinnamomvine, radish seed, cassia seed, oriental waterplantain rhizome, raw liquorice root and 10 kilograms of Chinese spirit. The wine basically maintains the mellow flavor of the Chinese spirit, is of sandy color and has light medicine taste and good mouthfeel; and various kinds of colloids, phospholipids, amino acids, bioactive substances, vitamins and mineral materials are contained, and through biochemical reactions, good effects of promoting digestion, reducing blood pressure and blood fat, adjusting blood sugar and providing nutrition and keeping healthcare are realized. After long-term drinking, the table adjustment wine can achieve the functions of adjusting the physiological functions, keeping people in young status, improving constitution, reducing weight, keeping people full of energy and the like. The table adjustment wine conforms to the present healthcare concept of pursuing an environment-friendly, low-energy and low-fat diet structure of the people. The table adjustment wine is taken once to twice before meals every day, 30-50 milliliters for each time.

The invention discloses lactobacillus acidophilus with anti-tumor, hypoglycemic and lipid-lowering activity. The name of the lactobacillus acidophilus is YL01, the classification name of the lactobacillus acidophilus is lactobacillus acidophilus, the preservation number of the lactobacillus acidophilus is CGMCC No.20085, the preservation date of the lactobacillus acidophilus is June 15, 2020, and the preservation unit of the lactobacillus acidophilus is China General Microbiological Culture Collection Center, Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The lactobacillus acidophilus YL01 has good acid and cholate tolerance, and can relieve diet-induced hyperlipidemia, relieve high-fat diet-induced mouse weight gain, significantly reduce postprandial blood sugar level, enhance the tolerance of the body to glucose and reduce insulin resistance. The lactobacillus acidophilus disclosed by the invention can be used for preparing fermented food for preventing and / or treating obesity and / or diabetes, and has a very wide application prospect.

Fatty liver was induced by administering agents for inducing organ inflammation to experimental animals to evoke insulin resistance and by rearing them with high-fat diets. As a result, steatohepatitis was successfully induced in the animals. The animals show pathological findings similar to those of humans. By using these model animals, substances for treating or preventing diseases can be efficiently screened and the efficacy of medicinal substances can be effectively evaluated.

The invention designs a novel lipid-lowering polypeptide P48. The novel lipid-lowering polypeptide P48 is prolonged in a half-life period, plays the role of a GLP-1 receptor agonist and also plays therole of a GLP-1 analogue to adjust the fat content of an individual. The P48 peptide can be used for inhibiting feed intake of a non-alcoholic fatty liver model mouse induced by high-fat diet, remarkably reduce the weight of an obese mouse, lower the blood fat level of the obese mouse, maintain the normal form of the liver, inhibit liver cell injury, reduce accumulation of lipid in the liver andvacuolar deformation of cells, increase the level of adiponectin leptin in blood, and give a play to the blood glucose reducing and blood fat regulating effects of the adiponectin leptin; meanwhile, the P48 peptide obviously improves insulin tolerance and sugar tolerance. The novel lipid-lowering polypeptide P48 of the invention has potential pharmaceutical application in preparation of drugs fortreating and preventing obesity or complications thereof, namely non-alcoholic fatty liver diseases.

The invention discloses application of bacillus coagulans in preparation of food or medicine for improving body function decline caused by hyperglycemia and hyperlipidemia, and belongs to the field of microbial strains. The invention discloses bacillus coagulans which is preserved in China General Microbiological Culture Collection Center (CGMCC) on November 10, 2021, the preservation number is CGMCC No.23766, and the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The strain has a certain effect on relieving weight rise, inflammatory response, tissue fat accumulation, memory ability decline, intestinal short-chain fatty acid reduction and intestinal flora imbalance caused by high-glucose and high-fat diet, and provides a new raw material and direction for screening food, health care products or medicines for regulating and controlling body function decline caused by hyperlipidemia and hyperglycemia.

The invention discloses a postbiotic prepared from lactobacillus rhamnosus and used for relieving fatty liver and obesity and application of the postbiotic, and belongs to the technical field of microorganisms and the technical field of medicines. The metagen prepared from the rhamnobacter rhamnosus CCFM1219 provided by the invention has the effects of relieving fatty liver and obesity: (1) the weight gain of high-fat diet mice is obviously relieved; (2) the blood glucose steady state of high-fat diet mice is obviously improved; (3) the liver fat accumulation and lesion of the high fat diet mouse are obviously inhibited; (4) the size of white fat cells is obviously reduced, the normal form of brown fat is maintained, and the browning of the white fat is promoted; (5) the levels of serum TC, GGT and ALP of high-fat diet mice are obviously reduced; and (6) the weight of white adipose tissues of the liver and the abdomen of the high-fat diet mouse is effectively reduced. Therefore, the metagen prepared from the lactobacillus rhamnosus CCFM1219 has a huge application prospect in preparation of products for preventing and / or treating fatty liver and obesity and even preventing and / or treating obesity and metabolic disorder related diseases.

The invention discloses lactobacillus casei for prevention and auxiliary treatment of type II diabetes and application of the lactobacillus casei. The lactobacillus casei LCZ has a remarkable functionof preventing type II diabetes and the process of the type II diabetes can be well prevented after the lactobacillus casei intervenes for two weeks; the weight increase of a high-fat diet mice can beintervened and delayed, and the oral glucose tolerance increase induced by high-fat diet is prevented; expression of intestinal tract iron-related protein (transferrin and iron transport carrier protein) can be improved, chronic inflammation caused by endotoxin entering tissue is reduced, and then the effect of lowering the hyperglycemia level is achieved. Due to the remarkable functional characteristics of the lactobacillus casei, the lactobacillus casei has wide application value in various forms of probiotic foods, such as probiotic tabletting candies and probiotic solid beverages.

The invention discloses a lactobacillus plantarum ZJUFYJ7 and an application of the lactobacillus plantarum ZJUFYJ7, and belongs to the technical field of biology. The preservation number of the lactobacillus plantarum ZJUFYJ7 is CCTCC (China Center for Type Culture Collection) NO: M 2020127. The lactobacillus plantarum ZJUFYJ7 provided by the invention has a very high survival rate and relatively strong gastrointestinal adhesive power in a gastrointestinal tract environment, can remarkably inhibit the reproduction of gastrointestinal pathogenic bacteria, has relatively strong free radical scavenging ability, improves the sugar intake of HepG2 hepatocytes and promotes the secretion of IL-10 by macrophages, and has a potential anti-inflammatory effect. Animal experiments prove that the lactobacillus plantarum ZJUFYJ7 can remarkably relieve hyperglycemia and insulin resistance induced by high-fat diet, and through colonization of the lactobacillus plantarum, intestinal flora disorder is improved, and bile acid and short-chain fatty acid metabolism is regulated and controlled, so that the effect of reducing blood sugar is achieved.

The invention discloses a building method of a dampness-heat asthma animal model. The method comprises the following steps of using high-fat diet to feed a rat, filling colibacillosis, and forming a dampness-heat syndrome type of the rat; when the high-fat diet is fed, using albumen and aluminium hydroxide normal saline mixing suspension liquid to sensitize the rat; after sensitizing, activating by the albumen normal saline solution, so as to obtain the dampness-heat asthma animal model. The method has the advantage that the traditional asthma animal model is organically combined with the traditional Chinese dampness-heat syndrome type animal model to form the traditional Chinese dampness-heat syndrome type asthma animal model, so as to apply for the traditional Chinese clinical asthma study, and facilitate the study of traditional Chinese asthma relieving medicine sieving.

The invention discloses a metabolic pathway of moringa oleifera seed antidiabetic serum potential markers based on metabonomics and a research method, relates to a research method of an action mechanism of natural vegetable drugs, and aims to solve the problem that the action mechanism of the natural vegetable drugs cannot be systematically and comprehensively evaluated by a conventional single pharmacological method. The metabolic pathway is realized through the following steps of: (1) detecting and analyzing serum metabolism products of rats suffering from diabetes induced through high-sugarhigh-fat diet and low-dosage streptozotocin and serum metabolism products of the rats after intervention with moringa oleifera seeds, through a nuclear magnetic resonance technique; (2) screening out14 moringa oleifera seed antidiabetic relevant serum potential markers and performing identification; and (3) screening out 5 moringa oleifera seed antidiabetic metabolic pathways and performing analysis. According to the metabolic pathway disclosed by the invention, the action mechanism of the moringa oleifera seeds for resisting diabetes can be evaluated comprehensively, efficiently, quickly and synthetically without bias from the integral level, and a basis is provided for clarification and further development of the action mechanism of the natural vegetable drugs for resisting diabetes.

The invention provides a method for establishing an SD-rat diabetes model through combination of high-fat diet with induction of STZ. An animal model with type-2 diabetes pathogenesis which is causedby insulin resistance and partial defects of islet B cells is established through clinical characteristics of simulation of human obesity and diabetes by using high-fat feed and STZ induction. SPG-grade SD male rats are divided randomly into normal control groups of 10 rats per group and diabetic groups of 20 rats per group. The rats of 4 weeks old are fed with high-fat diet so that induction of the insulin-resistant model is achieved, and low-dose tail-vein injection of STZ is performed 12 weeks after the rats are fed with the high-fat diet so that establishment of the animal model of diabetes can be induced. Through the method, the clinical characteristics of human type-2 diabetes which is caused by insulin resistance and hyposecretion of insulin can be simulated better, and compared with other modeling methods, the method has more scientific significance of combination of clinic and basic research.

The invention relates to a panax japonicas extract as well as a preparation method and application thereof. According to the invention, the method comprises the steps of preparation of panax japonicas raw material liquid, formation of a foam separation device and foam separation. By utilizing a high-fat diet molding technology, research is conducted in application and effect of the panax japonicas extract in an animal body, and the experimental result shows that the panax japonicas extract has favorable liver-protection and lipid-lowering activity, can obviously inhibit the formation of liver fibrosis, and has a good therapeutic effect on the liver fibrosis.

The invention provides new compositions or combinations thereof for the treatment of cancer. More specifically, the invention provides compositions or combinations thereof for cancer treatment including a high-fat diet. Specifically, the high-fat diet is characterized by having approximately 120 g / day or more, or approximately 70% or more of the total daily energy, from fat, based on a real weightof 50 kg. The diet is preferably a carbohydrate-restricted high-fat diet, and more preferably provided by a ketone formula and / or MCT oil. The dietary therapy by a high-fat diet of the present invention is provided along with surgical treatment, chemotherapy or radiation therapy, or combinations thereof.

The invention relates to the field of nutrient diets, in particular to a method with a nontherapeutic purpose for obtaining body weight reduction through a discontinuous ketogenic diet. The method forobtaining body weight reduction through the discontinuous ketogenic diet adopts a high-fat food composition and a ketogenic food composition as the diet. By use of an alternant mode of a high-fat diet and a ketogenic diet, the adverse effects of the high-fat diet and the ketogenic diet can be mutually offset, mental stress caused by long-term no ingestion of carbohydrates and intermittent fastingcan be alleviated, and meanwhile, the method can fully perform the weight reduction and fatty liver elimination functions of the ketogenic diet.

The invention relates to a molecular marker kit for formulating an individual weight reduction scheme. The kit comprises nucleotide shown in SEQ ID NO:1-10 and can comprise restriction endonucleases Hha I, Msp I and Bbv I. The kit is used for analyzing SNPs (single nucleotide polymorphisms) genotypes of a subject and issuing a comprehensive genetic predisposition analysis report, and nutritionists are invited to recommend a diet style (low fat diet, low carbohydrate diet and balanced diet) suitable to weight reduction to the subject, analyze intake calorie of the subject required every day according to the practical situation of the subject and individually arrange the proportion of three nutrient elements (fat, protein and carbohydrate) in three meals a day, so that healthy, scientific and effective weight reduction is achieved.

The invention discloses a function of tumor progress site 2 in treatment of fatty liver and type 2 diabetes as well as an application thereof. According to the invention, TPL2 gene knockout mice and wild type mice are taken as the experiment objects, through a high-fat diet-induced obesity mice model, the result shows that compared with the wild type C 57 mice, body weight of the TPL2 gene knockout mice is mitigated, the fasting blood glucose level is lower than that of a control group WT mice, and the hepatic dysfunction is obviously mitigated. Through intraperitoneal glucose tolerance experiment, the endurance of the TPL2 gene knockout mice on glucose is obviously enhanced. the mice liver tissue cholesterol content change result instructs that TPL2-KO mice fatty liver pathology of a HFD group (High fat diet) is obviously mitigated, and the lipid accumulation is obviously reduced. TPL2 can be taken as a drug target for treating fatty liver and / or type 2 diabetes, and its inhibitor can be used for preparing a drug to treating fatty liver and / or type 2 diabetes.

The invention belongs to the field of medicines, and relates to an isoindoline derivative compound, a preparation method and weight-losing application. The structural formula of the isoindoline derivative compound is shown as a formula I. The compound prepared by the invention can effectively reduce the weight of a mouse induced by high-fat diet and reduce the content of liver fat and epididymis fat, has a good weight-reducing effect, and can be used for preparing weight-reducing related medicines or health-care products.

The invention relates to a fecal biomarker for diagnosing or preventing diabetes mellitus, a detection reagent and application of the fecal biomarker. The excrement biomarker for diagnosing or preventing diabetes mellitus provided by the invention comprises one or more of 2-hydroxyhexanoic acid, phenylalanine, valine, acetyltryptophan, nonadecanoic acid, oxalic acid, picolinic acid, alpha-hydroxyisobutyric acid, indoleacetic acid, p-hydroxyphenylacetic acid, acetic acid, thyroxine, 4-hydroxyphenylpyruvic acid, myristic acid or phenylacetic acid. The fecal biomarker provided by the invention is high in sensitivity and specificity and good in predictability, and can be used for early diagnosis or prevention of diabetic people, especially diabetic people exposed by combination of long-term low-dose radiation and high-glucose and high-fat diet.

The invention relates to the technical field of microorganisms, and discloses a lactobacillus reuteri and its application. The preservation number of Lactobacillus reuteri CCFM8631 of the present invention is CGMCC No.14394, which can significantly improve the level of rat peripheral blood neurotransmitter 5-serotonin; restore the rat peripheral blood testosterone hormone level caused by a high-sugar and high-fat diet and the abnormal abundance of Blautia, Turicibacter, Oscillospira and Bifidobacterium in the intestinal flora; tolerance to simulated gastrointestinal fluid, rapid colonization in the intestinal tract, significantly improved the liver of rats with metabolic syndrome caused by high-sugar and high-fat diet , pathological damage of the duodenum and elevated levels of triglyceride and total cholesterol in serum, used to prevent, slow down or treat metabolic disorders such as metabolic syndrome, irritable bowel syndrome and anxiety and depression related to metabolic syndrome and other mental illness.